Acadia Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.www.acadia-pharm.com
6
MENTIONS
4
EPISODES
4
PODCASTS
Search complete. 6 mentions across 4 episodes found for "Acadia Pharmaceuticals".
Sep 25, 2026
speaker_0HOST
However, not all news is positive.
speaker_0HOST
Acadia Pharmaceuticals faced setbacks as its phase two trial for remlefnazarin missed primary endpoints in Alzheimer's disease psychosis, illustrating the challenges inherent in neurological drug development.
speaker_0HOST
Industry dynamics are further illustrated by Boehringer Ingelheim's strategic decision to offload its Shanghai CDMO to Ross Blood Products, reflecting ongoing localization trends within pharmaceutical manufacturing.
speaker_0HOST
Meanwhile, AstraZeneca's Breztri received its third asthma-related approval from the European Commission, reinforcing its commitment to expanding its respiratory portfolio across key geographies.
Bethany HillsGUEST
I'm really excited to be here again, and thanks to Analysis Group for inviting me to join.
Wayne PinesHOST
For the first time, we're joined by Dilesh Doshi, He is currently the Vice President of Global Health Economics and Outcomes Research at Acadia Pharmaceuticals.
Wayne PinesHOST
His team is responsible for generating real-world evidence to guide appropriate treatments for patients with neuropsychiatric illness and rare disorders.
Wayne PinesHOST
He has over 25 years of experience in the pharmaceutical industry.
26 MINS LATER
Wayne PinesHOST
And we're back.
Wayne PinesHOST
We're talking with James Signorovich of Analysis Group.
Wayne PinesHOST
with Bethany Hills of White & Case, with Vilesh Doshi of Acadia Pharmaceuticals.
Wayne PinesHOST
I want to start here with Bethany.
John PilcherGUEST
Yeah, so that's correct.
John PilcherGUEST
So with our first drug debut, we took it to the end of what's called Phase 2 clinical trials and then we partnered with a US company called Acadia Pharmaceuticals who did the last trial, the phase three trial, and then have done everything from the commercialization front and paid for all of that.
John PilcherGUEST
And so our return on that is royalties and milestone payments, which has been incredibly lucrative for us.
John PilcherGUEST
And we've had more than $500 million of income from that.
Annalee ArmstrongHOST
But we always kind of knew this was coming.
Annalee ArmstrongHOST
I know that earlier this year, I sat down with Acadia Pharmaceutical CEO, Catherine Owen Adams.
Annalee ArmstrongHOST
And she told me that as the CEO of a small biotech, she and other CEOs were working with the White House because they knew this was coming.
Annalee ArmstrongHOST
They knew that eventually they would likely come under scrutiny from the White House.